A5049054503- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Cancer Treatment and Pharmacology
- Breast Cancer Treatment Studies
- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Monoclonal and Polyclonal Antibodies Research
- Brain Metastases and Treatment
- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- Cancer Diagnosis and Treatment
- Ferroptosis and cancer prognosis
- Breast Lesions and Carcinomas
- Estrogen and related hormone effects
- Cancer Immunotherapy and Biomarkers
- Cancer-related Molecular Pathways
- Peptidase Inhibition and Analysis
- Radiopharmaceutical Chemistry and Applications
- Metastasis and carcinoma case studies
- Autophagy in Disease and Therapy
- Bone health and treatments
- Gastric Cancer Management and Outcomes
- HIV/AIDS Research and Interventions
- Cancer Cells and Metastasis
- Genetic factors in colorectal cancer
Chinese Academy of Medical Sciences & Peking Union Medical College
2016-2025
United World College of South East Asia
2025
Chongqing Medical University
2024
Sun Yat-sen University
2023-2024
Sun Yat-sen University Cancer Center
2023-2024
Zhejiang University
2022-2024
Children's Hospital of Fudan University
2024
Jiaxing University
2024
State Key Laboratory of Oncology in South China
2024
Nanjing University of Chinese Medicine
2024
To characterize the clinical and pathological features survival of patients with human epidermal growth factor receptor 2 (HER2)-low breast cancer in China.The China National Cancer Center database was used to identify 1,433 metastatic HER2-negative disease diagnosed between 2005 2015. Clinicopathological features, survival, prognosis information were extracted. Overall (OS) estimated using Kaplan-Meier method compared log-rank test. Prognostic factors associated OS analyzed Cox regression...
1022 Background: Currently, there are no standard ≥3 line regimens recommended for HER2-positive (IHC 3+, or IHC 2+/FISH+) advanced metastatic breast cancer, and HER2-targeting treatment HER2-low expressing 2+/FISH-, 1+) population. RC48-ADC is an innovative antibody-drug conjugate with a cleavable linker potent microtubule inhibitor payload MMAE that has bystanding effect in tumor cell killing. Methods: C001 CANCER (NCT02881138) was dose-escalation phase I study (0.5, 1.0, 1.5, 2.0, 2.5...
Human epidermal growth factor 2 (HER2)-low breast cancer, which is defined as HER2 1+ or 2+ in immunohistochemistry without gene amplification, accounts for a considerable part of all cancers. However, it remains controversial whether HER2-low cancer distinct entity. Our aim was to compare the clinicopathological features and survival outcomes between HER2-zero early cancer.The study retrospective analysis that enrolled 1,039 patients with available expression data single institute from 2013...
Abstract Proteolysis targeting chimeras (PROTACs) have emerged as a promising strategy for drug discovery and exploring protein functions, offering revolutionary therapeutic modality. Currently, the predominant approach to PROTACs mainly relies on an empirical design–synthesis–evaluation process involving numerous cycles of labor‐intensive synthesis‐purification bioassay data collection. Therefore, development innovative methods expedite PROTAC synthesis exploration chemical space remains...
Abstract Background Disitamab vedotin (DV; RC48‐ADC) is an antibody‐drug conjugate comprising a human epidermal growth factor receptor 2 (HER2)‐directed antibody, linker and monomethyl auristatin E. Preclinical studies have shown that DV demonstrated potent antitumor activity in preclinical models of breast, gastric, ovarian cancers with different levels HER2 expression. In this pooled analysis, we report the safety efficacy patients HER2‐overexpression HER2‐low advanced breast cancer (ABC)....
Abstract Purpose: This phase I study assessed the safety, tolerability, MTD, pharmacokinetics, antitumor activity, and predictive biomarkers of pyrotinib, an irreversible pan-ErbB inhibitor, in combination with capecitabine patients HER2-positive metastatic breast cancer (MBC). Patients Methods: received oral pyrotinib 160 mg, 240 320 or 400 mg once daily continually plus 1,000 mg/m2 twice on days 1 to 14 a 21-day cycle. Pharmacokinetic blood samples were collected 14. Next-generation...
Abstract In our phase Ib trial (ClinialTrials.gov Identifier: NCT03855358), benmelstobart (TQB2450), a novel humanized IgG1 antibody against PD-L1, plus antiangiogenic multikinase inhibitor, anlotinib, demonstrated promising antitumor activities in pretreated triple negative breast cancer (TNBC) patients. We conducted explorative analyses of genomic biomarkers to explore the associations with treatment response and survival outcomes. Targeted next generation sequencing (NGS) was undertaken...
Bladder cancer (BC) is the most common malignant tumor in urinary system. Although chemotherapy one of important adjuvant treatments for BC, drug resistance, non-specific toxicity and severe side effects are major obstacles to BC chemotherapy. Natural products have always been a leading resource antitumor discovery, with advantages excellent effectiveness, low toxicity, multi-targeting potency easy availability. In this study, we evaluated potential anti-tumor effect securinine (SEC),...
// Anjie Zhu 1 , Peng Yuan Feng Du Ruoxi Hong 2 Xiaoyan Ding 3 Xiuqing Shi 4 Ying Fan Jiayu Wang Yang Luo Fei Ma Pin Zhang Qing Li Binghe Xu Department of Medical Oncology, National Cancer Center/Cancer Hospital, Chinese Academy Sciences and Peking Union College(CAMS&PUMC), Beijing, China Sun Yat-sen University center, The State Key Laboratory Oncology in South China, Collaborative Innovation Center for Medicine, Guangzhou, Guangdong, Beijing Ditan Capital University, Yuhuangding Yantai,...
Background and Purpose: Moyamoya disease (MMD) is a rare steno-occlusive slowly progressing cerebrovascular disorder. The detailed mechanism of the underlying pathogenesis still blurry. Methods: Tandem Mass Tag-labeled quantitative proteomics was performed on serum-derived exosomes (SDEs) extracted from adult patients diagnosed with pure ischemic MMD or hemorrhagic healthy controls. Then mouse brain vascular endothelial cell (EC), human umbilical vein EC, neuroblastoma cell, hepatocyte were...
Objective This study aimed to explore possible associations between molecular subtypes and site of distant metastasis in advanced breast cancer (ABC). Methods 3577 ABC patients were selected from 21 hospitals seven geographic regions China 2012-2014. A questionnaire was designed collect medical information regarding demographic characteristics, risk factors, subtype, recurrence/metastasis information, disease-free survival (DFS). The cancers classified into Luminal A, B, HER2-enriched Triple...
There is mixed evidence on the influence of self-disclosure one's HIV status mental health, health behaviours and clinical outcomes. We studied patterns among parents living with HIV, factors that parental disclosure.This mixed-methods study was adults in care participating a assessing uptake pediatric index-case testing. They completed survey to provide demographic HIV-related information, assess partners, children others. ran generalized linear models determine associated disclosure...
This paper examines the complex and multifaceted relationship between population growth, economic development, resource allocation, social welfare, focusing on evolving concept of "optimal global population." It highlights how moderate growth can boost productivity living standards by fostering technological innovation driving industrial transformation. Conversely, unchecked intensifies issues such as depletion, environmental degradation, inequality, creating significant barriers to...
T cell exhaustion is important to protect the host from immunopathology during chronic viral infection, but it also impairs anti-tumor immunity (1-5). A fundamental unresolved question whether and how determined at onset of TCR signaling (6-8). Here we report an unexpected role Themis, a TCR-proximal molecule (9), in exhaustion. Chronic infection mice usually leads survival host. Surprisingly, Themis T-cell conditional knockout died severe CD8(+)-dependent lung showing Themis' importance...
Background Triple-negative breast cancer (TNBC) is an aggressive subtype with a poor prognosis. Although circular RNAs (circRNAs) have been implicated in progression, their roles TNBC remain poorly understood. In this study, we aimed to develop prognostic model for by constructing competing endogenous RNA (ceRNA) network. This network integrates circRNAs, long noncoding (lncRNAs), microRNAs (miRNAs), and messenger (mRNAs) identify potential biomarkers therapeutic targets improving clinical...
The BRIGHT-2 study (NCT05077449) is a randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy and safety of bireociclib plus fulvestrant (BF) vs. placebo (F) in Chinese female patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) advanced breast cancer (ABC) who had progressed on or after prior endocrine therapy (ET). Interim results were analyzed 70% progression-free survival (PFS) events across 64 centers China between December 8, 2021, March 28,...
Objective: Anlotinib is a novel tyrosine kinase inhibitor blocking angiogenesis. This study was performed to assess the efficacy and safety of anlotinib in patients with metastatic breast cancer. Methods: Patients HER2-negative cancer, who were pre-treated anthracycline or taxanes neoadjuvant, adjuvant, setting, had treatment failure after at least one prior chemotherapy regimen setting enrolled. administered 12 mg daily for 14 days 21-day cycle until disease progression unacceptable...
Abstract Purpose To evaluate the efficacy and safety of pamiparib in patients with locally advanced or metastatic human epidermal growth factor receptor 2-negative (HER2−) breast cancer, deleterious suspected germline BRCA1/2 mutations (g m). Methods In this open-label, phase II, multicenter study China (NCT03575065), triple-negative cancer (TNBC cohort) hormone receptor-positive (HR+)/HER2− (HR+/HER2− ≤ 2 prior lines chemotherapy received 60 mg orally twice daily 28-day, continuous cycles....
Six-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase 2 (PFKFB2) is a key regulator of glycolytic enzyme. This study identified whether PFKFB2 can regulate myocardial ferroptosis in ischemia/reperfusion (I/R) injury. Mice injury and H9c2 cells oxygen-glucose deprivation/reperfusion (OGD/R) models were established. expression was enhanced I/R mice OGD/R cells. Overexpression improves heart function mice. inhibits OGD/R-induced Mechanistically, overexpression activates the adenosine...
This study aims to explore the role of non-luminal disease score (NOLUS) for everolimus in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC). NOLUS has previously been established as an algorithm: (0-100) = - 0.45 × ER(%) 0.28 PR(%) + 0.27 Ki67(%) 73. Information was retrospectively collected from three centers China. Totally, 198 HR+/HER2- ABC complete records expression rates (%) ER, PR Ki67 were enrolled...